Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01949506 · ClinicalTrials.gov registry record · NA
(SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas
A NA study of Sarcoma,Soft Tissue and Stage IV Adult Soft Tissue Sarcoma, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT01949506 is a NA study of Sarcoma,Soft Tissue and Stage IV Adult Soft Tissue Sarcoma that has completed, run by Medical College of Wisconsin. The registered enrollment target is 9 participants, below the 86-participant average among 7 other Sarcoma,Soft Tissue trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01949506, a NA study of Sarcoma,Soft Tissue and Stage IV Adult Soft Tissue Sarcoma, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective study to document the local control rates with SBRT specifically for pulmonary metastases from soft tissue sarcoma. This study will prospectively document acute and late toxicity, quality of life (QoL), tumor control, and survival.
Conditions Studied
Interventions
- RADIATION SBRT
Study Locations (1)
Wisconsin
- Froedtert Hospital and Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-09-24 |
| Est. Completion | 2019-10-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01949506
The ClinicalTrials.gov registry entry for NCT01949506 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 7 other Sarcoma,Soft Tissue trials with a reported enrollment target (90% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sarcoma,Soft Tissue appearing as the primary indexed condition, and to 1 intervention - of which SBRT is the first listed.
NCT01949506 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT01949506 about?
NCT01949506 is a clinical study titled "(SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas". This is a prospective study to document the local control rates with SBRT specifically for pulmonary metastases from soft tissue sarcoma. This study will prospectively document acute and late toxicity, quality of life (QoL), tumor control, and survival.
What is the current status of trial NCT01949506?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2013-09-24. Estimated completion is 2019-10-04.
What conditions does trial NCT01949506 study?
This clinical trial studies the following conditions: Sarcoma,Soft Tissue, Stage IV Adult Soft Tissue Sarcoma.
What interventions are being tested in trial NCT01949506?
The interventions under investigation include: SBRT (RADIATION).
Who is sponsoring clinical trial NCT01949506?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01949506 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma,Soft Tissue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.